Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:alsoKnownAs |
gptkb:Gleevec
gptkb:imatinib |
| gptkbp:approvalYear |
2001
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XE01
|
| gptkbp:category |
protease inhibitor
antineoplastic agent |
| gptkbp:chemicalFormula |
C29H31N7O
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:discoveredBy |
gptkb:Brian_Druker
gptkb:Nicholas_Lydon |
| https://www.w3.org/2000/01/rdf-schema#label |
STI-571
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:patent |
gptkb:US5521184A
|
| gptkbp:sideEffect |
nausea
edema fatigue rash muscle cramps |
| gptkbp:target |
gptkb:BCR-ABL
gptkb:PDGFR gptkb:c-KIT |
| gptkbp:usedFor |
gptkb:gastrointestinal_stromal_tumor
gptkb:chronic_myeloid_leukemia leukemia |
| gptkbp:bfsParent |
gptkb:CHEMBL958
|
| gptkbp:bfsLayer |
6
|